273090 New Jersey’s experience with the SUID Case Registry

Monday, October 29, 2012 : 11:06 AM - 11:24 AM

Lisa Hartmann , Office of Performance and Accountability, Department of Children and Families NJ, Trenton, NJ
New Jersey has a population of nearly 9 million people representing a diverse population. Approximately one third of births are to foreign-born mothers. Each year about 250 infant deaths are identified and reviewed by the Child Fatality and Near Fatality Review Board (CFNFRB). Approximately 40% of the infant deaths identified for review had a cause or manner of death listed as ‘undetermined'. Once a case is reviewed and determined preventable or non-preventable, the case is entered into the Child Death Review web-based data collection system. Only when all information is entered and checked; and the final death certificate is obtained is the case considered cleaned and completed. New Jersey has reviewed 167 SUID cases since 2009. Of these, 107 were under age of 3 months, 70 were classified as SIDS and only 11 were determined preventable. Of the 167 SUID cases, 119 were not in a crib or bassinette, 89 were not on back at time of death, and 78 were sleeping with other people. Of the 22 suffocation/asphyxia SUID cases since 2009, 20 were sleep related. As a result of participating in the SUID Case Registry pilot program, New Jersey has instituted some practice and policy changes to improve SUID case investigation and create SUID prevention activities.

Learning Objectives:
Describe at least two strategies used by New Jersey’s SUID Case Registry pilot program to improve SUID case investigation and create state-wide SUID prevention initiatives.

Keywords: SIDS, Maternal and Child Health

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I am qualified to present because I have served as the Program Manager of the SUID grant in the state of NJ since 2010. I closely monitor the grant, case reviews, and data.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.